Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma.-Reference-Cited by-同舟云学术

Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:9030-9030
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Andtbacka Robert Hans Ingemar¹,Curti Brendan D.²,Kaufman Howard³,Daniels Gregory A.⁴,Nemunaitis John J.⁵,Spitler Lynn E.⁶,Hallmeyer Sigrun⁷,Lutzky Jose⁸,Schultz Stephen Michael⁹,Whitman Eric D.¹⁰,Zhou Karl¹¹,Karpathy Roberta¹²,Weisberg Jeffrey Ira¹³,Grose Mark¹⁴,Shafren Darren¹²

Affiliation:

1. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

2. Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR

3. Rush University Medical Center, Chicago, IL

4. UC San Diego Moores Cancer Center, La Jolla, CA

5. Mary Crowley Cancer Research Centers, Dallas, TX

6. St. Mary's Medical Center, Tiburon, CA

7. Oncology Specialists SC, Park Ridge, IL

8. Mount Sinai Medical Center, New York, NY

9. American Health Network Indiana, Indianapolis, IN

10. Atlantic Melanoma Center, Morristown, NJ

11. inVentiv Health Clinical, Bridgewater, NJ